Associated Papers
Inflammatory Giant Cell Carcinoma of the Lung: Clinicopathologic, Immunohistochemical, and Next-generation Sequencing Study of 14 Cases.
Suster DI et al.
The American Journal of Surgical Pathology, 2024
The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer.
Szpechcinski A et al.
International Journal of Molecular Sciences, 2024
Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.
Kunimasa K et al.
Cancer Medicine, 2020
EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer.
Zheng HY et al.
Current Medical Science, 2020
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
Namba K et al.
Bmc Cancer, 2019
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples.
Pepe F et al.
Journal of Clinical Pathology, 2019
Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.
Takahashi Y et al.
Cancer Science, 2018
Oncogene mutational analysis in Chinese gastrointestinal stromal tumor patients.
Chen Q et al.
Oncotargets and Therapy, 2018
Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A et al.
Plos Medicine, 2017
Protein-structure-guided discovery of functional mutations across 19 cancer types.
Niu B et al.
Nature Genetics, 2016
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
Inferring the functional effects of mutation through clusters of mutations in homologous proteins.
Yue P et al.
Human Mutation, 2010
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer (amsterdam, Netherlands), 2008
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
Hsieh RK et al.
Chest, 2005